♟️ Wednesday 28 October 2026 Wed, 28 Oct 2026

Transurban has clarified that the I-24 Southeast Choice Lanes award involves US$21 billion in present-value payments to Tennessee, rather than the previously published US$24.8 billion headline figure. The concession also includes revenue-sharing provisions that could increase the state’s take if toll revenues or returns exceed agreed thresholds.

Rumble Resources has outlined a preliminary A$86 million pre-tax NPV for Western Queen, with a 45% IRR and almost four years of planned underground production. The study also leaves room for tungsten upside, but financing, approvals and a feasibility study remain unresolved.

archTIS has reached a significant cash conversion milestone, with quarterly customer receipts exceeding operating payments for the first time since its Spirion acquisition. The cybersecurity company also reported higher margins, lower costs and fresh U.S. defence work, although its most closely watched enterprise licence remains unsigned.

Frasers Group has declared its A$0.65 per share cash offer for Accent Group best and final, removing the prospect of a higher bid from Frasers before the takeover closes. Accent shareholders now have until 29 January 2027 to decide whether immediate cash certainty outweighs the company’s standalone growth plans.

88 Energy has secured Westlawn Americas Offshore as a 40% partner in its South Prudhoe Project, bringing up to A$15.5 million towards the Augusta-1 well and related work. The deal reduces the company’s near-term funding burden while leaving it with a 60% interest and operatorship.

Big River Industries has carried its FY26 recovery into the new financial year, reporting 10.5% first-quarter revenue growth and a further lift in gross margin. The building-products group says its growth initiatives support above-market expansion, while a strategic review remains unresolved.

XPON Technologies has completed the Datisan disposal for $8.1 million in initial cash, repaid its short-term loan and redirected its attention to Wondaris and applied AI acquisitions. The company’s next test is whether that cash can translate into stronger platform growth.

Fortuna Metals has completed deeper drilling beneath its large inferred Mkanda rutile-graphite resource, returning broad mineralised intersections and a peak rutile grade of 3.43%. The company ended September with A$11.43 million in cash as it moves towards further resource definition and technical studies.

Zinc of Ireland has reported average recoveries of 93% silver, 97% lead, 58% zinc and 80% copper from three zinc leach residue sources as it accelerates ARGO toward a pilot plant in early 2027. The company also completed an A$3.2 million placement, while critical-mineral recoveries and commercial-scale milestones remain outstanding.

Aurelia Metals generated its strongest quarterly Cobar operating cash flow since 2018 as higher gold, copper and zinc production lifted cash to A$160.7 million. The company reaffirmed FY27 guidance while moving closer to a major Peak processing expansion.

Ore Resources has converted its Miriam drilling campaign into a 153,200-ounce JORC Mineral Resource, with most ounces shallow and Forrest still open along strike and at depth. A separate conceptual Exploration Target points to a further 200,000 to 400,000 ounces, but remains unconverted exploration potential.

Southern Palladium’s Bengwenyama project has emerged from its latest study with a sharply higher forecast value, a 30-year mining right and a much larger chrome contribution. The development case is stronger, but the project still requires permits, external funding and further technical confirmation.

LTR Pharma has moved ROXUS from signed US commercial agreements to its first fulfilled patient-specific prescriptions, while SPONTAN’s final Phase II report completes the pharmacokinetic dataset agreed with the FDA. The company ended September with A$18.2 million in cash and no debt.

Neurotech International has dosed the first patient in its pivotal Phase 3 trial of NTI164, with all six Australian sites now active and up to 200 children planned for enrolment. The milestone sits alongside FDA clearance and fresh funding, but quarter-end cash covered only 1.24 quarters of historical operating outflows.

Entropy Neurodynamics says all six patients in its early Phase 2 binge eating disorder cohort retained clinically meaningful improvement 12 weeks after treatment. The company is now widening TRP-8803’s development program while operating with $3.626 million in cash and an undrawn $2.6 million facility.

Andromeda Metals has produced 99.9986% purity High Purity Alumina at continuous pilot scale and raised A$3.04 million to advance its next study. But the Great White Project still needs about A$40 million in equity before a final investment decision.

Nexsen is pursuing a second Group B Streptococcus device through a proposed FlashDx joint venture while upgrading StrepSure after interim clinical data shifted its US FDA submission target to early 2027. The diagnostics developer ended September with $3.56 million in cash, equivalent to about four quarters of funding at the latest operating cash-flow rate.

Veris is using its FY26 results and first-quarter trading update to make the case that its transformation from surveyor to digital and spatial advisory firm is gaining traction. Revenue and underlying EBITDA rose, while the planned Aurecon acquisition adds a near-term test of whether the strategy can convert into stronger earnings.

Boss Energy has maintained FY27 production and cost guidance after a weather-disrupted quarter, while its new wide-spaced wellfield design points to production at Honeymoon through at least FY34. The next test is whether early operating data can validate the study’s assumptions and support a larger regional uranium hub.

SiteMinder is targeting mid-20s annual recurring revenue growth through FY30 and an adjusted EBITDA margin in the mid-20s, as it positions its hotel commerce platform for an AI-led shift in bookings and revenue management. The company entered that plan after FY26 revenue reached A$266 million and adjusted EBITDA margin rose to 10.6%.

Castile Resources has reaffirmed a striking A$1.07 billion pre-tax NPV8 for Rover 1, with bismuth now adding a fifth revenue stream. But the preliminary study still depends on substantial funding, unfinished testwork and a mine plan partly based on Inferred Resources.

Tasman Resources now has the regulatory green light for drilling at both Titan West and Parkinson Dam, but record rainfall has delayed its Fortescue-led Lake Torrens campaign. The explorer ended September with $5.4 million in cash and no debt, giving it reported funding capacity while it moves toward two separate drilling programs.

Global Gold Mining has reported flotation recoveries of up to 91.4% from laboratory testwork at its Sturec Gold Project in Slovakia, while ongoing drilling supplies data for the project’s pre-feasibility study. The company ended September with $6.134 million in cash after quarterly operating and investing outflows of $1.547 million.

Vitrafy has expanded its US blood and cell therapy partnerships while preparing Guardion for a planned medical device listing by the end of 2026. The company ended September with A$38.3 million in cash and term deposits, but expects spending to rise as validation and manufacturing accelerate.